MedTech Dive May 2, 2024
Nick Paul Taylor

PathAI is selling its diagnostics assets, including a Tennessee laboratory, but will continue to support its biopharmaceutical customers.

Dive Brief:

  • Quest Diagnostics said Wednesday it will buy PathAI’s diagnostic laboratory as part of a deal designed to “dramatically ramp” its capabilities in artificial intelligence and digital pathology.
  • The lab in Memphis, Tennessee, will become Quest’s AI and digital R&D and solutions center and support the company’s specialty pathology businesses. PathAI is retaining its biopharma lab.
  • Quest also secured a license to use PathAI’s digital pathology image management system and to be a preferred provider for the company’s biopharma clinical laboratory services. Neither party disclosed the terms of the deal.

Dive Insight:

PathAI has built a pathology...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Technology, Trends
Related Articles:
STAT+: NVIDIA’s Kimberly Powell touts progress on AI in drug discovery
Big pharma ignores low-cost migraine solution
Sanders: Weight loss drug could bankrupt healthcare system
J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition
Going beyond A, B & O: Thermo Fisher unveils DNA test for the rarest blood types

Share This Article